Acute Myeloid Leukemia Clinical Trials in St Louis, Missouri

17 studies are recruiting for acute myeloid leukemia in St Louis, Missouri right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

   This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid leukemia (AML). Cytarabine is a drug that inhibits some of …

   Stage

   Phase 2

   Ages

   18 to 59

   Site

   Washington University School of Medicine, St Louis, Missouri

   Locations

   186 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05554393 on ClinicalTrials.gov

2. Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

   This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabi…

   Stage

   Phase 2

   Ages

   18 to 59

   Site

   Washington University School of Medicine, St Louis, Missouri

   Locations

   226 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05554406 on ClinicalTrials.gov

3. MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

   This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrom…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Washington University School of Medicine, St Louis, Missouri

   Locations

   349 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05564390 on ClinicalTrials.gov

4. Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

   This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed in…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Washington University School of Medicine, St Louis, Missouri

   Locations

   227 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06317649 on ClinicalTrials.gov

5. A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

   This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and …

   Stage

   Phase 3

   Ages

   0 to 21

   Site

   Washington University School of Medicine, St Louis, Missouri

   Locations

   206 in total

   Run by

   Children's Oncology Group

   See if you can join NCT04293562 on ClinicalTrials.gov

6. A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

   Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 4 indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, …

   Stage

   Phase 1

   Ages

   0 and older

   Site

   Washington University in St. Louis School of Medicine, St Louis, Missouri

   Locations

   57 in total

   Run by

   Syndax Pharmaceuticals

   See if you can join NCT04065399 on ClinicalTrials.gov

7. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

   This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the earl…

   Stage

   Not phased

   Ages

   40 to 75

   Site

   Mercy Infusion Center - Chippewa, St Louis, Missouri

   Locations

   745 in total

   Run by

   Alliance for Clinical Trials in Oncology

   See if you can join NCT05334069 on ClinicalTrials.gov

8. Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

   The current standard of care treatment for adult patients with acute myeloid leukemia (AML) consists of chemotherapy and, if indicated, donor stem cell transplantation. Bleximenib blocks the interaction between a protein called menin and another protein called KMT2A in the leukemia cells. When this…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   US-St Louis MO-WASHU, St Louis, Missouri

   Locations

   82 in total

   Run by

   Stichting Hemato-Oncologie voor Volwassenen Nederland

   See if you can join NCT07223814 on ClinicalTrials.gov

9. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

   This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide informat…

   Stage

   Phase 1

   Ages

   Up to 22

   Site

   Cardinal Glennon Children's Medical Center, St Louis, Missouri

   Locations

   184 in total

   Run by

   PedAL BCU, LLC

   See if you can join NCT04726241 on ClinicalTrials.gov

10. Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

    A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin [GO]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who are unable to receive additional anthracyclines, or…

    Stage

    Phase 3

    Ages

    0 to 21

    Site

    Washington University School of Medicine in St. Louis, St Louis, Missouri

    Locations

    90 in total

    Run by

    PedAL BCU, LLC

    See if you can join NCT05183035 on ClinicalTrials.gov

11. Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML

    This trial represents a single institution phase I/II pilot study with the primary objective of establishing the safety and feasibility of generating and infusing ML NK cells after TCRαβ haplo-HCT.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT06158828 on ClinicalTrials.gov

12. Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

    The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Locations

    45 in total

    Run by

    Kura Oncology, Inc.

    See if you can join NCT06001788 on ClinicalTrials.gov

13. Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation

    This phase 2 study aims to confirm the efficacy observed in the prior phase 1 trial in Cohort 1 and to evaluate the safety of IFN-γ in combination with DLI in Cohort 2, the haploidentical donor alloSCT recipient cohort. The study will further contribute to this effort through the collection of leuk…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Washington University, St Louis, Missouri

    Locations

    3 in total

    Run by

    Sawa Ito, MD

    See if you can join NCT06529731 on ClinicalTrials.gov

14. Motixafortide for MRD Sensitization in AML

    This is a pilot phase I study evaluating the effect of motixafortide on determination of measurable residual disease (MRD) level in patients with acute myeloid leukemia (AML) who have completed induction treatment. Consenting and eligible patients will undergo standard of care (SOC) bone marrow and…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT07392970 on ClinicalTrials.gov

15. Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

    This phase I trial tests the safety, side effects, and best dose of SM08502 (cirtuvivint) alone and in combination with ASTX727 in treating patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Cirtuvivint may stop the growth of cancer cells by blocking some of the enzymes…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Locations

    22 in total

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT06484062 on ClinicalTrials.gov

16. Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

    The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 as a monotherapy, in double combination with Azacitidine and in triple combination with Azacitidine and Venetoclax in participants with relapsed or refractory…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Washington University School of Medicine, Siteman Cancer Center, St Louis, Missouri

    Locations

    16 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT06419634 on ClinicalTrials.gov

17. Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS

    This is a single institution, prospective study of the whole genome sequencing assay, ChromoSeq. Using prospectively collected patient data, coupled with physician surveys, the investigators seek to determine the feasibility of implementing ChromoSeq in addition to standard genomic testing, for pat…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT04986657 on ClinicalTrials.gov